Switching tenofovir disoproxil fumarate to tenofovir alafenamide results in a significant decline in parathyroid hormone levels: uncovering the mechanism of tenofovir disoproxil fumarate-related bone loss?

Berend J Van Welzen; Matheus A J Thielen; Tania Mudrikova; Joop E Arends; Andy I M Hoepelman

doi:10.1097/QAD.0000000000002238

Switching tenofovir disoproxil fumarate to tenofovir alafenamide results in a significant decline in parathyroid hormone levels: uncovering the mechanism of tenofovir disoproxil fumarate-related bone loss?

Berend J Van Welzen^*
, Matheus A J Thielen
, Tania Mudrikova
, Joop E Arends
, Andy I M Hoepelman

^*Corresponding author for this work

Research output: Contribution to journal › Article › Academic › peer-review

1 Downloads (Pure)

Abstract

: An increasing number of patients have been switched from tenofovir disoproxil fumarate (TDF) to tenofovir alafenamide because of its improved bone safety profile, although the pathophysiological mechanism is not fully understood. We show that serum parathyroid hormone levels drop significantly after the switch from TDF to tenofovir alafenamide. This observation supports the theories that TDF-related bone loss is parathyroid hormone-driven and that this effect is dose-dependent.

Original language	English
Pages (from-to)	1531-1534
Number of pages	4
Journal	AIDS
Volume	33
Issue number	9
Early online date	22 Apr 2019
DOIs	https://doi.org/10.1097/QAD.0000000000002238
Publication status	Published - 15 Jul 2019

Access to Document

10.1097/QAD.0000000000002238

vanwelzenFinal published version, 200 KBLicence: Taverne

Fingerprint

Dive into the research topics of 'Switching tenofovir disoproxil fumarate to tenofovir alafenamide results in a significant decline in parathyroid hormone levels: uncovering the mechanism of tenofovir disoproxil fumarate-related bone loss?'. Together they form a unique fingerprint.

Cite this

Van Welzen, B. J., Thielen, M. A. J., Mudrikova, T., Arends, J. E., & Hoepelman, A. I. M. (2019). Switching tenofovir disoproxil fumarate to tenofovir alafenamide results in a significant decline in parathyroid hormone levels: uncovering the mechanism of tenofovir disoproxil fumarate-related bone loss? AIDS, 33(9), 1531-1534. https://doi.org/10.1097/QAD.0000000000002238

@article{31a51b9f445949ef9d3e698406bdb21b,

title = "Switching tenofovir disoproxil fumarate to tenofovir alafenamide results in a significant decline in parathyroid hormone levels: uncovering the mechanism of tenofovir disoproxil fumarate-related bone loss?",

abstract = ": An increasing number of patients have been switched from tenofovir disoproxil fumarate (TDF) to tenofovir alafenamide because of its improved bone safety profile, although the pathophysiological mechanism is not fully understood. We show that serum parathyroid hormone levels drop significantly after the switch from TDF to tenofovir alafenamide. This observation supports the theories that TDF-related bone loss is parathyroid hormone-driven and that this effect is dose-dependent.",

author = "\{Van Welzen\}, \{Berend J\} and Thielen, \{Matheus A J\} and Tania Mudrikova and Arends, \{Joop E\} and Hoepelman, \{Andy I M\}",

year = "2019",

month = jul,

day = "15",

doi = "10.1097/QAD.0000000000002238",

language = "English",

volume = "33",

pages = "1531--1534",

journal = "AIDS",

issn = "0269-9370",

publisher = "Lippincott Williams \& Wilkins",

number = "9",

}

Switching tenofovir disoproxil fumarate to tenofovir alafenamide results in a significant decline in parathyroid hormone levels: uncovering the mechanism of tenofovir disoproxil fumarate-related bone loss? / Van Welzen, Berend J; Thielen, Matheus A J; Mudrikova, Tania et al.
In: AIDS, Vol. 33, No. 9, 15.07.2019, p. 1531-1534.

Research output: Contribution to journal › Article › Academic › peer-review

TY - JOUR

T1 - Switching tenofovir disoproxil fumarate to tenofovir alafenamide results in a significant decline in parathyroid hormone levels

T2 - uncovering the mechanism of tenofovir disoproxil fumarate-related bone loss?

AU - Van Welzen, Berend J

AU - Thielen, Matheus A J

AU - Mudrikova, Tania

AU - Arends, Joop E

AU - Hoepelman, Andy I M

PY - 2019/7/15

Y1 - 2019/7/15

N2 - : An increasing number of patients have been switched from tenofovir disoproxil fumarate (TDF) to tenofovir alafenamide because of its improved bone safety profile, although the pathophysiological mechanism is not fully understood. We show that serum parathyroid hormone levels drop significantly after the switch from TDF to tenofovir alafenamide. This observation supports the theories that TDF-related bone loss is parathyroid hormone-driven and that this effect is dose-dependent.

AB - : An increasing number of patients have been switched from tenofovir disoproxil fumarate (TDF) to tenofovir alafenamide because of its improved bone safety profile, although the pathophysiological mechanism is not fully understood. We show that serum parathyroid hormone levels drop significantly after the switch from TDF to tenofovir alafenamide. This observation supports the theories that TDF-related bone loss is parathyroid hormone-driven and that this effect is dose-dependent.

UR - https://www.scopus.com/pages/publications/85069237751

U2 - 10.1097/QAD.0000000000002238

DO - 10.1097/QAD.0000000000002238

M3 - Article

C2 - 31021851

SN - 0269-9370

VL - 33

SP - 1531

EP - 1534

JO - AIDS

JF - AIDS

IS - 9

ER -

Switching tenofovir disoproxil fumarate to tenofovir alafenamide results in a significant decline in parathyroid hormone levels: uncovering the mechanism of tenofovir disoproxil fumarate-related bone loss?

Abstract

Access to Document

Other files and links

Fingerprint

Cite this